Foley Represents Milwaukee Bucks in Development of High-Tech, Adjustable Thermal Bench
March 22, 2019
Foley & Lardner LLP represented the NBA’s Milwaukee Bucks in connection with its development of a high-tech, adjustable thermal bench for its players. The specifications for the customized performance seating was developed by the Bucks and designed to enhance on-court performance by maintaining elevated body temperature and proper anthropometrics when players are seated.
Foley’s representation included protecting the Bucks’ intellectual property and negotiating with Figueras Seating USA for the engineering and manufacture of seating meeting the Bucks’ specifications.
The state-of-art player bench can be heated to 106 degrees to maintain optimal muscle temperature. The seats can be individually elevated or lowered at a touch of button to accommodate player heights without blocking spectator sightlines.
Partner Aaron Tantleff and Special Counsel Matt Swietlik led the Foley team.
Read more about the Bucks’ famed bench here.
Foley’s representation included protecting the Bucks’ intellectual property and negotiating with Figueras Seating USA for the engineering and manufacture of seating meeting the Bucks’ specifications.
The state-of-art player bench can be heated to 106 degrees to maintain optimal muscle temperature. The seats can be individually elevated or lowered at a touch of button to accommodate player heights without blocking spectator sightlines.
Partner Aaron Tantleff and Special Counsel Matt Swietlik led the Foley team.
Read more about the Bucks’ famed bench here.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."